×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARGX – argenx se - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARGX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/17
03:51 pm
argx
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Citigroup Inc. from $681.00 to $796.00. They now have a "buy" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Citigroup Inc. from $681.00 to $796.00. They now have a "buy" rating on the stock.
4/11
04:01 pm
argx
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
Medium
Report
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
4/11
10:13 am
argx
argenx SE (NASDAQ: ARGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $715.00 price target on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $715.00 price target on the stock.
4/10
05:47 pm
argx
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
Medium
Report
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
4/9
08:10 am
argx
argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $720.00 price target on the stock.
Medium
Report
argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $720.00 price target on the stock.
4/8
01:00 am
argx
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
Low
Report
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
3/17
08:02 am
argx
argenx SE (NASDAQ: ARGX) was upgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating.
Low
Report
argenx SE (NASDAQ: ARGX) was upgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating.
3/12
07:22 am
argx
argenx SE (NASDAQ: ARGX) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "sell" rating to a "hold" rating.
Low
Report
argenx SE (NASDAQ: ARGX) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "sell" rating to a "hold" rating.
Date
Time
Symbol
Company Name
Action
%Chg
2/27/2025
01:00 am
ARGX
argenx se - american depositary shares
BEAT
Report
0.3%
argenx se - american depositary shares
2/27/2025
01:00 am
ARGX
argenx se - american depositary shares
BEAT
Report
0.3%
argenx se - american depositary shares
2/27/2025
01:00 am
ARGX
argenx se - american depositary shares
BEAT
Report
0.3%
argenx se - american depositary shares
2/27/2025
01:00 am
ARGX
argenx se - american depositary shares
BEAT
Report
0.3%
argenx se - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/14
06:00 am
argx
Form 6-K ARGENX SE For: Apr 11
Medium
Report
Form 6-K ARGENX SE For: Apr 11
3/20
06:47 am
argx
Form 20-F ARGENX SE For: Dec 31
Low
Report
Form 20-F ARGENX SE For: Dec 31
2/12
09:17 am
argx
Form SCHEDULE 13G/A ARGENX SE Filed by: FMR LLC
Low
Report
Form SCHEDULE 13G/A ARGENX SE Filed by: FMR LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/12
argenx announces closing of global offering
7.2%
8/6 argenx SE - (NASDAQ: ARGX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 4.4%
3/4 argenx SE - (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $255.00 price target on the stock. 4.4%
10/1 argenx SE - (NASDAQ: ARGX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 4.1%
5/23 argenx SE - (NASDAQ: ARGX) had its "overweight" rating re-affirmed by analysts at Piper Jaffray Companies. They now have a $182.00 price target on the stock, up previously from $161.00. 3.6%
5/15 argenx SE - (NASDAQ: ARGX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 3.5%
6/27 argenx SE - (NASDAQ: ARGX) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 2.8%
12/9 Form 6-K ARGENX SE For: Dec 07 2.7%
6/18 argenx SE - (NASDAQ: ARGX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 2.6%
10/24 argenx reports third quarter 2019 financial results and provides business update 2.6%
8/6 argenx SE - (NASDAQ: ARGX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 4.4%
3/4 argenx SE - (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $255.00 price target on the stock. 4.4%
10/1 argenx SE - (NASDAQ: ARGX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 4.1%
5/23 argenx SE - (NASDAQ: ARGX) had its "overweight" rating re-affirmed by analysts at Piper Jaffray Companies. They now have a $182.00 price target on the stock, up previously from $161.00. 3.6%
5/15 argenx SE - (NASDAQ: ARGX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 3.5%
6/27 argenx SE - (NASDAQ: ARGX) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 2.8%
12/9 Form 6-K ARGENX SE For: Dec 07 2.7%
6/18 argenx SE - (NASDAQ: ARGX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 2.6%
10/24 argenx reports third quarter 2019 financial results and provides business update 2.6%
TOP News Decliners
2/27
Form 6-K ARGENX SE For: Feb 27
-5.7%
9/9 argenx SE - (NASDAQ: ARGX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.7%
1/13 Form 6-K ARGENX SE For: Jan 13 -4.7%
5/22 Form 6-K ARGENX SE For: May 22 -4.7%
5/9 Form 6-K ARGENX SE For: May 09 -3.5%
3/31 Form 20-F ARGENX SE For: Dec 31 -3.3%
6/25 argenx SE - (NASDAQ: ARGX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $156.00 price target on the stock. -3.0%
1/22 argenx SE - (NASDAQ: ARGX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $172.00 price target on the stock. -2.8%
9/27 argenx SE - (NASDAQ: ARGX) is now covered by analysts at Wells Fargo & Co. They set a "market perform" rating on the stock. -2.7%
9/3 argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference -2.5%
9/9 argenx SE - (NASDAQ: ARGX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.7%
1/13 Form 6-K ARGENX SE For: Jan 13 -4.7%
5/22 Form 6-K ARGENX SE For: May 22 -4.7%
5/9 Form 6-K ARGENX SE For: May 09 -3.5%
3/31 Form 20-F ARGENX SE For: Dec 31 -3.3%
6/25 argenx SE - (NASDAQ: ARGX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $156.00 price target on the stock. -3.0%
1/22 argenx SE - (NASDAQ: ARGX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $172.00 price target on the stock. -2.8%
9/27 argenx SE - (NASDAQ: ARGX) is now covered by analysts at Wells Fargo & Co. They set a "market perform" rating on the stock. -2.7%
9/3 argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference -2.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: